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Background: Important candidate genes involved in the ovarian response to exogenous FSH are the estrogen
receptor genes (ESRs), since the effects of estrogens on follicle growth, maturation and oocyte release. It is known
that some markers of ovarian stimulation can help to personalize the treatment, adjusting the dose of exogenous
rFSH, thus preventing excessive wear of the patient. Inspired on this information we aimed to analyze four different
polymorphisms in the estrogen receptor genes ESR1: rs2234693/T-397C (PvuII) and rs9340799/A-351G (Xbal) and
ESR2: rs4986938/G1082A (RsaI) and rs1256049/A + 1730G (AluI), and their association with assisted reproduction
outcomes in Brazilian women that underwent in vitro fertilization (IVF).
Methods: A cross-sectional study was performed involving 136 infertile women less than 39 years of age with
normal ovarian reserve. Patients were divided according to the same COH protocol for statistical analysis. The
Taqman assay was used for PvuII and XbaI of ESR1, and RsaI and AluI of ESR2 genotyping. Serum estradiol and FSH
were measured by Elisa assay.
Results: The PvuII (ESR1) TT and RsaI (ESR2) GG genotypes were associated with a longer induction period and
higher doses of medication (p < 0.03). The XbaI (ESR1) AA genotype was associated with better COH results,
including a larger number of follicles, mature oocytes, embryos, and good quality embryos (p < 0.05). The AluI GG
genotype showed an association with the Ovarian Hyperstimulation Syndrome (OHSS) (p = 0.03). According to the
haplotype analysis of ER1 (PvuII/XbaI), we demonstrated that the CA combination increases by 0.68 the number of
good quality embryos while the TG decreases it by 0.71 (p = 0.04).
Conclusion: ER polymorphisms have an association with the assisted reproduction outcomes in Brazilian women.
Keywords: Estrogen receptor gene, Polymorphism, In vitro fertilization, Controlled ovarian hyperstimulationIntroduction
Infertility is a health problem that affects 15–20% of
couples at a reproductive age [1], with several medical,
emotional, and social implications. The use of in vitro
fertilization (IVF) has improved the treatment prospects
for infertility by diverse causes. In developed countries,
it is estimated that 2-3% of all births are results of IVF
procedures [2].* Correspondence: bianca.bianco@hotmail.com
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unless otherwise stated.IVF is a multistep process that still has limited
successful rates regardless of constant improvement in
laboratory performance, as it also depends on interindivid-
ual variability factors such as ovarian response after
controlled ovarian hyperstimulation (COH). Both quanti-
tative and qualitative factors in oocyte production have a
high influence on the IVF outcome, since increasing the
number of mature oocytes improves the selection of viable
embryos for transfer [3].
Although low response rates can lead to cycle
cancellation, high responses are troublesome as they can
trigger a serious medical iatrogenic condition – the ovarian
hyperstimulation syndrome (OHSS). This unpredictableThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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represents one of the most challenging issues of IVF
treatment safety. Previously published data indicates
that age, Follicle Stimulating Hormone (FSH), Estradiol,
Inhibin B, Anti-Müllerian hormone (AMH) serum levels,
and antral follicle count (AFC) are clinically relevant
predictors of oocyte yield [4-8], but none of this markers
have significant predictive value when considered
alone [6,8].
Besides these parameters, a complementary strategy
involves studying the pharmacogenetics of the COH
response. Candidate genes involved in the reproductive
system present single-nucleotide polymorphisms (SNPs)
that can lead to amino acid change in the protein
and/or affect gene expression, and seem to be an import-
ant factor in changing the cellular and tissue effect of
gonadotropins [9].
Important candidate genes involved in the ovarian
response to exogenous FSH are the estrogen receptor
genes (ESRs), since the effects of estrogens on follicle
growth, maturation, and oocyte release have been well
reported [10]. Estrogens extend the action of FSH on
granulosa cells by promoting their proliferation and
increasing their expression of FSH receptors [11]. In
addition, they also play a regulatory role in endometrial cell
growth and differentiation in the reproductive cycles [12],
and consequently, exert a crucial effect on endometrial
preparation for implantation [13]. Blastocysts and two-cell
embryos express estrogen receptors (ERs) mRNA, which
supports the possibility that estrogens also play a role in
early embryonic development [14].
Two subtypes of ERs have been identified in humans,
ERα and ERβ, encoded by ESR1 (6q25.1) and ESR2
(14q23.2) genes, respectively. In folliculogenesis, ERα are
expressed predominantly in the theca layer and mediates
estrogen proliferative actions. ERβ, expressed in granulose
cells of growing follicles in different stages of develop-
ment, promotes the differentiation and antiproliferative
effects required for reaching the antral stage [15].
Prior findings suggested that genetic variability of ESRs
may be important for advances in the diagnosis and
treatment of infertility. Associations with the ovarian
response in COH/IVF have been studied the most, regard-
ing two SNPs: rs2234693/T-397C (defined by the cleavage
site of restriction enzyme PvuII) and rs9340799/A-351G
(defined by the cleavage site of restriction enzyme XbaI)
in ESR1, and two other identified polymorphisms in ESR2:
rs4986938/G1082A (defined by the cleavage site of
restriction enzyme RsaI) and rs1256049/A + 1730G
(defined by the cleavage site of restriction enzyme
AluI) [1].
Inspired by these findings, the purpose of the present
study was to analyze, for the first time in infertile
Brazilian women, the association of ESR1 (PvuII andXbaI) and ESR2 (AluI and RsaI) polymorphisms with
the controlled ovarian hyperstimulation response, as well as
human reproductive outcomes in a normal ovarian reserve
group with a fixed dose of recombinant FSH protocol.
Material and methods
Patients
A prospective cross-sectional study was performed
on 380 women who underwent the first cycle of
high-complexity IVF between September 2011 and
September 2013 at the Human Reproduction and
Genetics Center of the Faculdade de Medicina do ABC,
Santo André, São Paulo, Brazil.
One hundred and thirty-six out of 380 patients met
the inclusion criteria, which were age ≤38 years old, FSH
≤10mIU/mL, AMH ≥0.5 ng/mL, normal ovulatory cycles
(25–35 interval days), and both ovaries present with no
morphological abnormalities. We excluded patients with
a history of inadequate ovulatory response, prior ovarian
surgery, radio/chemotherapy, moderate/severe endometri-
osis (grades III and IV), and endocrine diseases such as
hyperprolactinemia (PROL ≥25 ng/mL), thyroid dysfunction
(TSH ≥4.5mIU/mL), obesity (body mass index ≥30), and
polycystic ovary syndrome.
The indications for IVF were tubal factor infertility
(33%), male factor infertility (54%), and unexplained
infertility (13%). The investigation as to the cause of
infertility included a complete medical history and physical
examination, hormonal and biochemical profile, semen
analysis of the partner, investigation of immunological and
genetic abnormalities, hysterosalpingography, and hyster-
oscopy. All patients were investigated for endometriosis
with laparoscopy performed if there were symptoms or
abnormalities on the physical examination, CA 125 or
imaging tests (ultrasound or/and pelvic magnetic resonance).
In all women less than 36 years of age with no other
infertility causes, laparoscopy was routinely performed. If
the cause of infertility could not be diagnosed in spite of
this evaluation, the case was considered unexplained.
Anatomic tubal abnormalities were diagnosed with
hysterosalpingography and/or laparoscopy, and male
factor infertility was classified according to the cri-
teria of the World Health Organization [16].
Written informed consent, approved by the local
Ethics in Research Committee, was obtained from all
patients participating in the present study.
Ovarian stimulation protocol and IVF outcome
COH was conducted according to the GnRh (Gonadotropin
Releasing Hormone) antagonist protocol with a fixed dose
of recombinant FSH (rFSH) per day. The dose of rFSH was
chosen between 100 or 200 IU according to age (100 IU
below 37 years of age and 200 IU for patients 37 years of
age or more), antral follicle count and/or prior inductions.
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menstruation, continuing between 9 and 11 days when the
two biggest follicles reached 18 mm in diameter. The
GnRh agonist was initiated on the 6th day or when at
least one follicle had reached 14 mm. Cycles were
canceled when follicles did not show any satisfactory re-
sponse until the 8thday of rFSH. Final follicle maturation
was achieved using 250 μg of hCG followed by oocyte
retrieval 36 hours later.
The number of mature oocytes was calculated for
both IVF and in vitro fertilization with sperm injection
(ICSI) patients. Oocytes were considered mature if they
reached meiosis II (MII) stage within 4 hours after oocyte
retrieval. The total number of embryos was calculated by
counting the embryos after visualization of the 2 pro-
nuclei. Embryos with at least 5 blastomeres and less than
20% of fragmentation on day 3 were classified as good
quality embryos [17]. A maximum of two embryos
were transferred into the uterus guided by abdominal
ultrasound visualization on days 3 or 5, according to
the number and evolution of the embryos. Six hundred
micrograms of micronized progesterone were used for
luteal support. A positive βhCG test (≥10 IU/L) was
conducted 12 days after embryo transfer.
With regard to the controlled ovarian stimulation
response, we considered as Poor response < 3 growing
follicles or less than 4 collected oocytes according to
the ESHRE consensus (2011) on the definition of
poor responders by Ferraretti et al. [18], Satisfactory
response between 4 to 12 follicles, Hyperresponse between
13 to 19 follicles, and Ovarian Hyperstimulation
Syndrome (OHHS) with 20 or more follicles or/and
clinical symptoms such as ascites, hematological
changes (hemoconcentration, hypercoagulation), pleural
effusion, and liver abnormalities according to the classifi-
cations proposed by Golan et al. [19].
Analysis of FSH, Estradiol and AMH
Serum FSH, Estradiol (E) and AMH levels were mea-
sured on the initial day of the rFSH/COH. FSH and
E were mensured by radioimmunoassay (RIA) using
commercial RIA kits (ELFA, Enzyme Linked Fluorescent
Assay, Mini-VidasBioMerieux, Hazelwood, Missouri, USA).
AMH was measured by enzyme-linked immunosorbent
assay (ELISA) using the AMH Gen II kit by Beckman
Coulter, Inc (Brea, CA, USA). The measurement was
realized by automated Labotech (Alka Technology®).
Values are presented in concentration of ng/ml (convert
to SI units: 1 ng/ml = 7,14pM). The analytic sensibility
was 0.008 ng/ml.
Genotyping
Peripheral blood was collected from each patient in an
EDTA-containing tube. Genomic DNA was extractedfrom lymphocytes of peripheral blood according to the
salting out standard protocol (Lahiri and Numberger,
1991). Detection of the polymorphisms Pvull and Xbal
of the ESR1 gene, and AluI and RsaI of the ESR2gene
was performed using the TaqMan system by real-time
polymerase chain reaction (PCR). Primers and probes
were commercially available and provided by Life
Technologies (Foster City, California, USA). Assays
were performed with TaqMan Universal Master Mix with
50 to 100 ng of DNA per reaction. PCR conditions were
40 cycles of denaturation at 95°C (15 seconds) and anneal/
extension at 60°C (1 minute). A random subset (*20% of
samples) was repeatedly genotyped in order to avoid false
results, and all the samples had concordant findings.
Statistical analysis
The analyses were performed using SPSS® 18.0, considering
a p value lower than 0.05 or 5% as statistically significant.
Allele and genotypic frequencies were calculated by allele
counting, and the Hardy-Weinberg (H-W) Equilibrium for
each polymorphism was tested using the Chi-square test.
The Shapiro-Wilk test was used to assess the distribution
of the numerical variables. Than for the association of the
numerical variables with the genotypes we used Kruskal-
Wallis/Mann–Whitney tests for the no parametric variables
and one way ANOVA/Student's t tests for the single
parametric variable – FSH. To calculate the level of signifi-
cance, we used the average for the parametric variables
and the median for the no parametric variable.
We investigated the associations between all tested SNPs
and overall ovarian stimulation outcomes under the differ-
ent genetic models. Genotypic Model (AA versus Aa versus
aa), Dominant Model (AA +Aa versus aa), and Recessive
Model (AA versus Aa + aa). The Bonferroni correction was
applied for the Genotypic Model and we now considered
p value lower than 0,016 (0,05/3) as statistically significant.
Chi-square or Fisher's Exact tests were used to associate
the genotype frequencies of the polymorphisms and
the categorical variables regarding ovarian stimulation
outcomes.
Furthermore, linkage disequilibrium (LD) among the
studied polymorphisms located in the ESR1 gene
(rs2234693 and rs9340799) and theERS2 gene (rs4986938
and rs1256049) was measured by D’ using Haploview
software. The Expectation-Maximization algorithm was
calculated to estimate haplotype frequencies; haplotypes
with a frequency less than 0.01 were excluded from the
analysis. PLINK software was used to associate haplotypes
with both numerical and categorical variables of the study.
Results
Characteristics of patients and COH outcome
A total of 136 women were included in this study once
they meet the inclusion criteria. The mean age of the
Table 1 Incidence of the polymorphisms PvuII, XbaI, RsaI,
and AluI genotypes and alleles in the studied population
Polymorphism Genotype N %
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estradiol levels on D3 of the cycle were 6.2 ± 1.7mIU/mL
and 50.6 ± 33.8 pg/mL, respectively. The mean number
of follicles and oocytes was, respectively, 6.7 ± 4.8 and
6.5 ± 4.7 per patient. The mean number of embryos
was 4.2 ± 3.2, with 2.7 ± 2.5 embryos classified as good
quality embryos.
According to the COH protocol, 104 patients used rFSH
at 100 IU per day and were classified as the homogenous
protocol group. Considering the total group, patients used
an average of 9.2 days of medication and 1144 IU of rFSH
per cycle.
Regarding the classification of the COH response,
63.2% presented with a satisfactory response, 6.6% showed
a hyperresponse, and 4.4% developed the OHSS, while
25.7% were classified as poor responders. The fertilization
rate was 67% and the pregnancy rate was 32.3% per
embryo transfer.
The characteristics of patients and COH outcome did
not differ significantly according to the infertility factor.
Polymorphism analysis
The genotype distribution and allelic frequency of the
four single nucleotide polymorphisms are summarized
on Table 1. Genotype frequencies observed during this
study were in Hardy-Weinberg equilibrium.
There was a significant association between PvuII with
days and dose of medication. Individuals with the TT
genotype used a bigger amount of rFSH (IU of rFSH)
than of TC and CC, both when genotypes were com-
pared alone: TT 1309 IU versus TC 1107 IU (p = 0.006)
and versus CC 1105 IU (p = 0.008), and when the reces-
sive model was used: TT 1309 IU versus TC + CC
1106 IU (p = 0.03). After confirming these results in the
analyses of the homogenous dose group with the
100 IU/day protocol, we also found that the TT genotype
used more days of medication than TC and CC (p = 0.009)
(Table 2) and TC +CC (p = 0.005) (Table 3).
Regarding the XbaI polymorphism we found statistical
significant association in the AA genotype and better
results of IVF, both in the total group and in the homo-
geneous protocol group (protocol of rFSH 100UI/day).
This results include a larger number of follicles, mature
oocytes, embryos and good quality embryos. In the
total group, both the recessive and the dominant
model reached statistical significance, but this results
were confirmed in the homogeneous group only in the
recessive model (Table 4). Interestingly, we also observed,
in the total group, that the GG genotype used a bigger
dose of rFSH in the dominant model: GG 1200UI ± 430.1
versus AG+AA 1134.7UI ± 398.4 (p = 0.035).
Relative to the RsaI, there was a significant association
between the genotypes and days of medication both
in the total (p = 0.001) and the homogenous group(p = 0.011), demonstrating that the wild GG genotype
used more days of medication. Besides, GG patients of the
homogenous group used also a bigger amount of rFSH
(p = 0,005) and although there was just one women with
the AA genotype, the results remain the same with the
recessive model: GG versus AG+AA (Table 5).
Finally, the analyses of the AluI polymorphism showed
that in the total group, the GG genotype had a statisti-
cally significant increased frequency of OHSS: 83.3%
(p = 0,03) when compared with GA: 16.7% and AA: 0%
(p = 0.03).
There were no differences between patients classified
as poor responders and normal responders with respect
to genotype distribution.
The haplotype analysis of the ERS1 (PvuII/XbaI)
showed that patients with the CA haplotype increased
by 0.68 the number of good quality embryos compared
with individuals without this combination. Additionally,
the TG haplotype decreased by 0.71 the number of good
quality embryos (p = 0.04). Since we included male factor
infertility, the results including number and quality of
embryos should be reviewed in future assessments.
According to the variable age there was no significant
difference between the age of the patients and the different
genotypes of the polymorphisms that could compromise
the COH results.
Table 2 Association of the PvuII genotypes separately and the outcome of COH/IVF in the homogenous rFSH dose
group (100 IU per day)
Variables PvuII C/T - rs2234693
TT TC CC χ2 p
N Median Minimum Maximum N Median Minimum Maximum N Median Minimum Maximum
Age (years) 16 33,5 27 37 54 32 26 37 35 31 24 37 0,41 0,521
BMI (kg/m2) 14 22,23 16,8 28,73 52 24,46 17,71 31,62 35 23,9 19,49 31,14 2,72 0,26
Estradiol (pg/ml) 16 39,67 27,06 253,58 54 46,445 28,14 346,9 35 45,53 28,66 90,22 1,99 0,37
Follicles 16 4 0 15 54 6 0 19 35 5 0 28 0,97 0,62
Oocytes 15 4 0 15 49 6 0 19 33 5 0 28 1,13 0,57
Mature oocytes 15 4 0 15 49 4 0 17 33 4 0 25 0,89 0,64
Embryos 13 4 0 14 43 3 0 14 30 4 1 17 1,66 0,44
Good quality
embryos
12 1,5 0 7 43 2 0 11 30 3 0 12 1,23 0,54
Days of rFSH 13 10 9 14 45 9 7 13 31 9 8 12 8,06 0,018*
Dose of rFSH (UI) 13 1000 900 1400 45 900 700 1300 31 900 800 1200 8,06 0,018*
N: Number of Individuals; SD: Standard deviation; *p < 0.05. Results of Kruskal-Wallis (represented by χ2).
de Mattos et al. Journal of Ovarian Research  (2014) 7:114 Page 5 of 9Discussion
The prior results, regardless of ER gene polymorphism and
their relation with the IFV outcome, are still controversial.
This might be due to the heterogeneity of the studied
populations regarding the ovarian reserve and the varied
exposures including different doses of recombinant FSH
for controlled ovarian hyperstimulation.
Ovarian stimulation can be viewed as a dynamic test
for the resting ovarian follicle pool [20]. Secondary to
the decline in follicle pool with age, the ovarian response
to FSH diminishes with age [21]. The European Society
of Human Reproduction and Embryology (ESHRE)
consensus of poor response, published in 2011, com-
pared 3,825 women entering the first cycle of IVF,
showing that the cancelation rate and the occurrenceTable 3 Association of the PvuII genotypes and the outcome
per day) in the recessive model
Variáveis PvuII C/T - rs2234693
TT
N Median Mínimum Maximum
Age (years) 16 33,5 27 37
BMI (kg/m2) 14 22,23 16,8 28,73
Estradiol (pg/ml) 16 39,67 27,06 253,58
Follicles 16 4 0 15
Oocytes 15 4 0 15
Mature oocytes 15 4 0 15
Embryos 13 4 0 14
Good quality embryos 12 1,5 0 7
Days of rFSH 13 10 9 14
Dose of rFSH (UI) 13 1000 900 1400
N: Number of Individuals; SD: Standard deviation; *p < 0.05. Mann–Whitney results rof poor responders (<4 oocytes) increases with age.
They identified more than 50% of poor response in
women over 40 years of age [18].
It is clear, therefore, that when patients 40 years old or
more are included in a group with younger women in
order to compare ovarian response with genetic markers,
the results will be compromised because of the difference
in the response with increased age.
As we know that follicle depletion increases six times
after 39 years of age [3,22], and most clinical trials
considered important changes in ovarian response
after 38 years of age [23,24], we excluded patients
more than 38 years of age in the present study.
Also, a recent published study revealed that when
patients classified as poor responders with a COHof COH/IVF in the homogenous rFSH dose group (100 IU
TC + CC U p
N Median Minimum Maximum
89 32 24 37 466 0,16
87 24,24 17,71 31,62 466 0,16
89 45,83 28,14 346,9 555 0,16
89 6 0 28 619,5 0,41
82 5 0 28 512 0,30
82 4 0 25 522 0,35
73 3 0 17 440,5 0,68
73 2 0 12 422,5 0,84
76 9 7 13 259,5 0,005*
76 900 700 1300 259,5 0,005*
epresented by U.
Table 4 Association of the XbaI genotypes and the outcome of COH/IVF in the homogenous rFSH dose group (100 IU
per day) in the Dominant Model
Variáveis XbaI A/G - rs9340799
AA AG + GG U p
N Median Mínimum Maximum N Median Minimum Maximum
Age (years) 41 32 24 37 64 34,5 28 38 439 0,061
BMI (kg/m2) 41 23,81 17,71 31,14 60 24,46 16,8 31,62 1077,5 0,29
Estradiol (pg/ml) 41 43,98 27,06 88,91 64 46,035 28,14 346,9 1224 0,56
Follicles 41 6 0 28 64 5 0 18 1009 0,046*
Oocytes 38 5,5 0 28 59 5 0 18 859,5 0,052
Mature oocytes 38 5 0 25 59 4 0 17 840,5 0,037*
Embryos 35 4 2 17 51 3 0 14 558,5 0,003*
Good quality embryos 35 3 0 12 50 1 0 11 562 0,004*
Days of rFSH 36 9 8 13 53 9 7 14 813,5 0,22
Dose of rFSH (UI) 36 900 800 1300 53 900 700 1400 813,5 0,22
N: Number of Individuals; SD: Standard deviation; *p < 0.05. Mann–Whitney results represented by U.
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200 IU of rFSH, only 10% continued to be classified as
poor responders, while 85% became regular responders
(≥3 ≤ 19 follicles), with 5% even developing an OHSS [25].
This shows that patient response can totally change if we
increase the dose of rFSH. This finding confirms the huge
importance of using fixed dose protocols when you want
to compare the ovarian response for COH. In our study
we first included patients with 100 and 200 IU of rFSH
because the definitions of poor response in literature do
not consider the same dose of medication used for
controlled ovarian hyperstimulation, and even in the
2011 ESHRE consensus of poor ovarian response,
only protocols with at least 150 IU of rFSH per day
were available for comparison. However, in our view,Table 5 Association of the RsaI genotypes and the outcome o
per day) in the Recessive model
Variáveis RsaI G/A- rs256049
GG
N Median Mínimum Maximum
Age (years) 95 32 24 37
BMI (kg/m2) 92 24,115 17,71 31,62
Estradiol (pg/ml) 95 42,11 27,06 346,9
Follicles 95 5 0 28
Oocytes 89 5 0 28
Mature oocytes 89 4 0 25
Embryos 79 3 0 17
Good quality embryos 78 2 0 12
Days of rFSH 82 9 7 14
Dose of rFSH (UI) 82 900 700 1400
N: Number of Individuals; SD: Standard deviation; *p < 0.05. Mann–Whitney results r
** Individuals with the allele A had better results of COH even thought their averagthe ovarian response for COH should be compared
according to the dose of rFSH used for induction, as it can
totally change the results, as discussed earlier. In order to
avoid this bias, we chose to separate a homogenous group
with a fixed dose of 100 IU of rFSH per day and to analyze
for the first time the relation between the ER polymor-
phisms and this COH protocol. Unfortunately, in
order to focus on an optimal selection of the study
sample, we faced one of the obstacles present in most
pharmacogenetic studies, i.e., a small sample size.
Nevertheless, we believe that the heterogeneity in the
age of the patients and the dose of rFSH for COH might
be responsible for the wide range of results.
The first pharmacogenetic investigation in COH/IVF,
by Georgiou et al. in 1997, was focused on the ESR1f COH/IVF in the homogenous rFSH dose group (100 IU
GA + AA U p
N Median Minimum Maximum
10 35 31 37 275,5 0,029**
9 24,34 16,8 28,71 355,5 0,49
10 49,395 40,3 253,58 292,5 0,046*
10 5 0 13 423 0,57
8 6,5 0 13 338 0,81
8 4 0 11 343,5 0,87
7 3 1 5 247 0,64
7 1 0 3 190,5 0,18
7 8 7 9 107,5 0,005*
7 800 700 900 107,5 0,005*
epresented by U.
e age values were higher than individuals with the genotype GG.
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25 to 35 years of age with tubal or unexplained infertility
and 100 controls. All patients used the same protocol of
COH with 225 IU of gonadotrophins per day. They
found that the PvuII TT genotype was associated with
decreased pregnancy rates when 2–3 consecutives cycles
were analyzed. Since then, there have been few studies
comparing the relation between ER polymorphisms and
the COH/IVF outcome.
In 1999, Sundarranjan et al. found an association
between PvuII CC and a smaller number of follicles,
oocytes, embryos, and pregnancy rate. The studied
group consisted of unexplained infertility patients between
24 and 39 years of age using a 200 IU rFSH daily COH
protocol, but increasing the dose to 300 IU when the
follicular number was not adequate [27].
Controversially, Altmae et al., in 2007, found better
results of IVF in the PvuI CC genotype in relation to
the number of follicles, oocytes, and the level of estradiol
on the day of hCG. They also described an association
between the C allele and smaller doses of rFSH per good
quality embryo. The authors showed that patients with
XbaI GG had higher estradiol levels on the day of hCG
and estradiol levels per follicle, than the AA genotype.
However they included patients up to 45 years of age, a
fact that can change the results of COH as discussed
earlier. Their group also included patients with endometri-
osis [28]. It has been suggested that endometriosis might be
a leading cause of ovarian dysfunction due to alterations in
estrogen and progesterone gene expression [29]. Therefore,
in our view, patients with endometriosis should be
excluded when comparing the results of COH/IVF,
since there is a discussion as to impaired ovarian re-
serve due to the disease, especially in moderate and
severe degrees.
Sequentially, in 2009, Ayvaz et al. confirmed PvuI
CC as a prognostic marker for better results of IVF,
including the number of mature oocytes, pregnancy
rate, and embryo quality. The authors compared 107
fertile women with 104 unexplained infertility patients
and described an association between infertility with
the genotypes TT and TC for the PvuI and AA XbaI
polymorphisms [30].
A prior study by De Castro et al., in 2004, presented
an original multilocus analysis of FSHR 680 – ESR1
PvuII - ESR2 AluI. Similar to our group, they analyzed
170 patients 33 ± 2.55 years of age with a dose of
100–200 IU rFSH using a protocol for COH including
tubal and male factor infertility. The comparison was
made between poor responders (<4 follicles) and high
responders, defined by the author as patients with a
follicle production higher than the mean value of
ovarian follicles in the total cohort (>10 follicles). The
FSHR Ser – PvuII T – AluI G was better representedin poor responders [31]. Unfortunately, XbaI was not
included in their study.
Anagnoston et al. had totally different results in 2012
in their multigenetic model with FSHR Asn/Asn – ERS1
PvuII CC presenting the worst profile of ovarian induc-
tion in 109 IVF women [32]. Furthermore, a different
approach was used by Anagnoston in 2013 when he
evaluated the number of mutated alleles of PvuI and
XbaI and the results of COH/IVF in 203 women. The
mutated alleles C (Pvul) and G (Xbal) were associated
with the worst quality embryos and smaller estradiol
levels on the hCG day [33]. To prepare this analysis they
considered that the two genes had necessarily the same
behavior as wild and mutated alleles, a fact that has not
been confirmed. They also included women up to
45 years of age and endometriosis.
Boudjenah et al. [9] published a study with thirteen
SNPs that reportedly influence the outcome of IVF and
427 women. They presented a positive association
between the AluI GG and the number of oocytes and
estradiol levels on the hCG day. They also selected a
homogenous group of 112 women under 38 years of
age without endometriosis and found that patients
with AluI AA required more exogenous gonadotrophins
for COH.
In the present study we demonstrated an association
between the amount of medication used for COH and
the PvuII polymorphism where patients with PvuII TT
used a larger amount of rFSH. Even when we separated
a group with exactly the same dose of rFSH per day
(100 IU daily), we found more days of use and conse-
quently a larger total dose of rFSH in the TT genotype.
These results are in agreement with prior findings by
Georgiou et al. [26], Altmae et al. [27], and Ayvaz et al.
[30], which showed the PvuII CC genotype improving
response and follicular quality, as had been described
before [26,28,30], resembling De Castro et al.[31] who
described the Pvull C allele frequency as being lower
among poor responders (≤ 3 follicles).
Our study is the first to find an association between
the XbaI and the COH outcome. The AA genotype is
strongly associated with better results showing more
follicles, oocytes, embryos, and good quality embryos.
This association was seen even in the total group as
in the group with the homogeneous dose. Moreover,
in the total group we observed a larger amount of
rFSH used for COH in the GG genotype.
Compared with the three studies that also analyzed
the ERS2 XbaI, Anagnostou et al. [33] similarly showed
association between the mutated G allele with worst
quality embryos and lower levels of estradiol on the
hCG day, which is different from Altmae et al. [28], who
found a larger dose of estradiol on the hCG day and per
follicle in the GG genotype [28,33]. As discussed earlier,
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of patients with endometriosis and older than 38 years of
age by our study, as it can significantly change the re-
sponse to COH. Furthermore, we conducted the first
study with a fixed rFSH dose protocol of 100UI per day.
Ayaz et al. [30] found a better fertilization rate in
the GG genotype and association between XbaI AA
and infertility. As we included male infertility our
fertilization rate was not considered, but the frequency of
the genotypes of our patients was in accordance with the
infertility group of their study.
Difference in ethnicity of the population group
could also play a role in contributing to the variation.
Screening of the ESR2 RsaI was seen in the Altmae
et al. [28] study in an Estonian population, and the
frequency of the genotypes is in agreement with our
study, with a rare occurrence of the mutated homozy-
gous AA (0.7%). We had only one patient with this
genotype, which can interfere with the statistical
results. Nonetheless, we found a statistical association
between RsaI GG and a larger amount of rFSH used
for ovarian induction. No other associations were
found in literature.
As to AluI polymorphism, the frequency of the geno-
types could be compared with the Spanish group of
De Castro et al. [31]. Although their study found no
association when analyzing the polymorphism alone,
they described an association with poor responders in
the multilocus model FSHR Ser – PvuII T – AluI G
[31]. Controversially, we had a statistical relation between
AluI GG and HOSS. Our results were similar to
Boudjenah et al. [9] who found an association between
AluI GG and better results of COH and IVF in comparasion
to AluI AA.
The FSHR gene is the genetic factor studied most
often regarding COH. It was observed that the FSHR
680Ser variant is associated with elevated baseline FSH
levels and elevated gonadotropin requirements during
COH [1,31,34]. Estrogens extend the action of FSH on
granulose cells by promoting their proliferation and
increasing their expression of FSH receptors [11]. Thus, a
multilocus rather than a marker-by-marker statistical
analysis might be a promising predictive tool for
COH outcome, but the small size of the samples are
a limitation factor for this kind of analysis. Although
it is very difficult to select a sample of women with
the same characteristics regardless of the infertility
factor and ovarian reserve, using the exact same dose of
medication for COH, differences in these characteristics
can totally change the results.
Conclusion
ER gene polymorphisms are associated with the results
of COH. ERS1 XbaI AA is associated with better resultsof COH, and AluI GG is associated with OHSS, while
PvuII TT, XbaI GG, and RsaI GG are associated with a
larger amount of rFSH in IVF cycles. More studies with
larger samples are needed to confirm these results. Also,
clinically well selected samples taking into account
different COH protocols with the same dose of medication
would be necessary in order to compare the COH
outcomes, increasing the possibility of a true association.
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